Polen Capital Management LLC Has $5.29 Million Stake in Adaptive Biotechnologies Corporation $ADPT

Polen Capital Management LLC grew its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 11.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 325,767 shares of the company’s stock after buying an additional 34,570 shares during the period. Polen Capital Management LLC’s holdings in Adaptive Biotechnologies were worth $5,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in ADPT. California State Teachers Retirement System raised its stake in shares of Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after acquiring an additional 933 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after acquiring an additional 1,119 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock worth $120,000 after acquiring an additional 1,532 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. Finally, Diversified Trust Co. raised its stake in shares of Adaptive Biotechnologies by 5.6% in the fourth quarter. Diversified Trust Co. now owns 42,200 shares of the company’s stock worth $685,000 after acquiring an additional 2,224 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on ADPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Morgan Stanley dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.57.

Adaptive Biotechnologies Price Performance

ADPT opened at $18.73 on Friday. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -56.76 and a beta of 2.15. The firm has a 50 day simple moving average of $14.50 and a 200 day simple moving average of $15.67. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.90 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. Adaptive Biotechnologies’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.20) earnings per share. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, insider Susan Bobulsky sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00. Following the completion of the sale, the insider directly owned 416,775 shares of the company’s stock, valued at $7,501,950. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 19,037 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $14.23, for a total transaction of $270,896.51. Following the sale, the chief operating officer directly owned 377,802 shares of the company’s stock, valued at approximately $5,376,122.46. This trade represents a 4.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 516,654 shares of company stock valued at $7,509,691. 5.70% of the stock is currently owned by corporate insiders.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.